Interní Med. 2003; 5(7): 342-347

Revmatoidní artritida - diagnóza a léčba

MUDr. David Suchý
Oddělení klinické farmakologie, FN Plzeň

Keywords: rheumatoid arthritis, corticosteroids, DMARDs, biological treatment.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D. Revmatoidní artritida - diagnóza a léčba. Interní Med. 2003;5(7):342-347.

Revmatoidní artritida je chronické autoimunitní onemocnění kloubů charakterizované nespecifickým zánětem periferních kloubů. V minulosti byla léčba postavena na nesteroidních antirevmaticích a chorobu modifikujících lécích v pozdější fázi onemocnění. Nyní je v léčbě uplatňován agresivnější přístup. Dostupnost biologických léků a leflunomidu umožňuje ještě intenzivněji ovlivnit rozvoj strukturálního postižení a disability pacientů.

Rheumatoid arthritis - diagnosis and treatment

Rheumatoid arthritis is a chronic, autoimmune disease characterized by nonspecific inflamation of peripheral joints. Historicaly, the management of RA has been based on treatment with nonsteroidal antiinflamatory drugs and with disease-modifying drugs administered to patients in later phase. Current a more aggresive approach is being recomended. Recently, the availability of biologics agents and leflunomide leads to a more intensive effect on structural damage and patients disability.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vencovský J. Systémová autoimunitní onemocnění minimum pro praxi. 1vyd Praha, Triton 1998.
    2. Pavelka K, et al. Pokroky v revmatologii. 1 vyd Praha Alter 1996.
    3. Pavelka K. Terapie revmatoidní artritidy. Remedia 2003; 1: 23-34.
    4. Pavelka K. Revmatoidní artritida. Practicus 2003; 1: 39-42.
    5. Olejárová M. Nesteroidní antirevmatika v terapii revmatických onemocnění. Remedia 2002; 12: 349-355.
    6. Bennet A. Overwiew of nimesulide. Rheumatology 1999; 38 (suppl 1): 1-3. Go to original source... Go to PubMed...
    7. Hallyar J,Bjarnanson I. NSAIDs, COX-2 inhibitors, and the gut. Lancet 1995; 346: 521-522. Go to original source... Go to PubMed...
    8. Lee JI, Burckart GJ. Nuclear factor kappa-B: Importand transcription factor and therapeutics target. J Clin Pharmacol 1998; 38: 981-993. Go to original source... Go to PubMed...
    9. Pavelka K. Sulfasalazin v léčbě revmatických onemocnění. Čes Revmatol 1998; 6: 113-122.
    10. The multicentre trial group.Controlled trials of D-penicillamine in severe rheumatoid arthritis.Lancet 1973; 1: 275-280. Go to PubMed...
    11. Weiblatt ME, Kaplan M, Germain BF, et al. Methotrexat in rheumatoid arthritis: a five year prospective multicentre study. Arthritis Rheum 1994; 37: 1492-1498. Go to original source... Go to PubMed...
    12. Maťha V, et al. Cyklosporin A. Praha: Avicenum 1994.
    13. Dostál C. Imunologie revmatických chorob: cyklosporin a FK 506. Medicina 1998; 9: 21.
    14. Tugwell P, BombardierC, Gent M, et al.Low dose cyclosporin versus placebo in patients with reumatoid arthritis.Lancet 1990; 335: 1051-1055. Go to original source... Go to PubMed...
    15. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe reunmatoid arthritis. N Eng J Med 1995; 333: 137-141. Go to original source... Go to PubMed...
    16. Pavelka K. Cyklosporin v léčbě revmatoidní artritidy.Čes Revmatol 1997; 7: 120-126.
    17. Stocley IH. Drug interactions. 4 th ed. Oxford: Blackwell Scientific Publications 1996.
    18. Prakash A, Jarvis B. Leflunomide: Areview of its use in active rheumatoid arthritis. Drugs 1999; 58: 1137-1164. Go to original source... Go to PubMed...
    19. Emery P. Disease modification in rheumatoid artrhritis with leflunomide. Scan J Rheumatol 1999; 28 Suppl. 112: 9-14. Go to original source... Go to PubMed...
    20. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double blind, randomized, multicentre trial. European leflunomide Study Group. Lancet 1999; 353: 259-266. Go to original source... Go to PubMed...
    21. Carteron NL.Cytokines in rheumatoid arthritis:trials and tribulations. Molecular Medicine Today 2000; 6: 315-323. Go to original source... Go to PubMed...
    22. Salfeld J, et al Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 1998; 41: (suppl. 9) 57.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.